Evidence map›Paper›PMID 37293153›Full record

ArticleAmerican journal of cancer research2023

Structural, topological, and functional characterization of transmembrane proteins TMEM213, 207, 116, 72 and 30B provides a potential link to ccRCC etiology.

Joanna Wesoly, Natalia Pstrąg, Kamil Derylo, Barbara Michalec-Wawiórka, Natalia Derebecka, Hanna Nowicka, Arkadiusz Kajdasz, Katarzyna Kluzek, Malgorzata Srebniak, Marek Tchórzewski and 2 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Joanna WesolyLaboratory of High Throughput Technologies, Adam Mickiewicz University Poznan, Poland.
Natalia PstrągLaboratory of High Throughput Technologies, Adam Mickiewicz University Poznan, Poland.
Kamil DeryloDepartment of Molecular Biology, Maria Curie-Sklodowska University Lublin, Poland.
Barbara Michalec-WawiórkaDepartment of Molecular Biology, Maria Curie-Sklodowska University Lublin, Poland.
Natalia DerebeckaLaboratory of High Throughput Technologies, Adam Mickiewicz University Poznan, Poland.
Hanna NowickaLaboratory of High Throughput Technologies, Adam Mickiewicz University Poznan, Poland.
Arkadiusz KajdaszLaboratory of Human Molecular Genetics, Adam Mickiewicz University Poznan, Poland.
Katarzyna KluzekLaboratory of Human Molecular Genetics, Adam Mickiewicz University Poznan, Poland.
Malgorzata SrebniakDepartment of Clinical Genetics, Erasmus Medical Center The Netherlands.
Marek TchórzewskiDepartment of Molecular Biology, Maria Curie-Sklodowska University Lublin, Poland.
Zbigniew KwiasDepartment of Urology and Urological Oncology, Poznan University of Medical Sciences Poznan, Poland.
Hans BluyssenLaboratory of Human Molecular Genetics, Adam Mickiewicz University Poznan, Poland.
Adam Mickiewicz University in Poznań · PLMaria Curie-Skłodowska University · PLErasmus MC · NLPoznan University of Medical Sciences · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to their involvement in the development of various cancers Transmembrane Proteins (TMEMs) are the focus of many recent studies. Previously we reported TMEM de-regulation in clear cell Renal Cell Carcinoma (ccRCC) with TMEM213, 207, 116, 72 and 30B being among the most downregulated on mRNA level. TMEM down-regulation was also more pronounced in advanced ccRCC tumors and was potentially linked to clinical parameters such as: metastasis (TMEM72 and 116), Fuhrman grade (TMEM30B) and overall survival (TMEM30B). To further investigate these findings, first, we set off to prove experimentally that selected TMEMs are indeed membrane-bound as predicted in silico, we verified the presence of signaling peptides on their N-termini, orientation of TMEMs within the membrane and validated their predicted cellular localization. To investigate the potential role of selected TMEMs in cellular processes overexpression studies in HEK293 and HK-2 cell lines were carried out. Additionally, we tested TMEM isoform expression in ccRCC tumors, identified mutations in TMEM genes and examined chromosomal aberrations in their loci. We confirmed the membrane-bound status of all selected TMEMs, assigned TMEM213, and 207 to early endosomes, TMEM72 to early endosomes and plasma membrane, TMEM116 and 30B to the endoplasmic reticulum. The N-terminus of TMEM213 was found to be exposed to the cytoplasm, the C-terminus of TMEM207, 116 and 72 were directed toward the cytoplasm, and both termini of TMEM30B faced the cytoplasm. Interestingly, TMEM mutations and chromosomal aberrations were infrequent in ccRCC tumors, yet we identified potentially damaging mutations in TMEM213 and TMEM30B and found deletions in the TMEM30B locus in nearly 30% of the tumors. Overexpression studies suggested selected TMEMs may take part in carcinogenesis processes such as cell adhesion, regulation of epithelial cell proliferation, and regulation of adaptive immune response, which could indicate a link to the development and progression of ccRCC.

Indexed as

ccRCCgene expressionsubcellular localizationtransmembrane protein

Identifiers

PMID37293153
PMCPMC10244102
OpenAlexW4379966315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.